The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
New digital health companion uses friendly, jargon-free communication to help users better understand reports
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
India continues to face a major maternal nutrition challenge, with nearly 60% of women affected by anaemia and more than 70% experiencing calcium deficiency
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Subscribe To Our Newsletter & Stay Updated
